HOW TO SELL A SMALL MIRACLE.HOW TO SELL A SMALL MIRACLE.

There are few therapy areas where the gap between scientific achievement and public confidence is as wide as it is in Alzheimer's disease. In the space of five years, the field has delivered the first disease-modifying therapies in its history – while simultaneously prompting advisory committee resignations, a reimbursement standoff in the UK, a meta-analysis describing the benefit as ‘trivial’, and a succession of high-profile trial failures across amyloid, tau and metabolic targets.^1–4

Both things are true at once. That is precisely the problem, and precisely why this moment matters to anyone whose job is to translate science into public understanding.

At TVF, we think the Alzheimer's story has become the defining case study in a broader challenge facing medical communications: how do you communicate genuine, hard-won, incremental progress in a culture that has been trained to expect breakthroughs? The answer will shape not just dementia, but every field where biology is complex, effect sizes are modest and patience is in short supply.

In this article, we have identified six forces shaping the Alzheimer’s landscape and, with them, six challenges for how the field is understood and communicated.

1. The original sin: approving a hypothesis, not a result

To understand today's scepticism, you have to return to the decision that created it.

When the first anti-amyloid antibody reached the US market, it did so through the Accelerated Approval pathway, based on its ability to reduce amyloid plaques in the brain rather than clear evidence that it improved patients’ symptoms or slowed the disease. The reasoning was defensible on paper: removing amyloid was considered a reasonable sign that the drug was affecting the disease, the unmet need was overwhelming, and confirmatory evidence was expected to follow. ⁵

But the decision went against the overwhelming recommendation of the regulator’s own advisory committee, which concluded that the evidence presented did not establish clinical benefit. Several members resigned in protest. That sequence did something more damaging than approve a controversial drug. It turned a scientific debate about whether amyloid is a cause of Alzheimer’s into a wider debate about the regulatory process and trust in the institutions making these decisions.

The consequence is that every subsequent anti-amyloid result – including the genuinely positive ones – has been read through the lens of that first controversy. When trust is spent early, later evidence has to work far harder. This is a communications lesson as much as a regulatory one: the framing established at first approval becomes the interpretive frame for the entire class.

2. The modest-effect problem

The next generation of antibodies finally produced the result the field had been waiting for: evidence of a clinical benefit. Lecanemab and donanemab have both demonstrated statistically significant slowing of decline in people with early Alzheimer’s disease. ^6–11

And yet the debate has not settled. The benefits seen in these trials were modest, and whether they amount to a meaningful difference for patients remains contested. That is especially true when weighed against the risks of amyloid-related brain swelling and bleeding, the burden of regular infusions and the need for close monitoring.¹²

A 2026 meta-analysis made headlines by concluding that the overall effect was, in essence, negligible. Critics immediately pointed out that it combined results from seven different antibody treatments, only two of which are currently licensed anywhere in the world.¹³ ¹⁴ That is an important limitation. But the fact that the headline travelled further than the caveat tells you something important about the information environment in which these treatments are being judged.

In several national health systems, the question of whether these benefits justify the cost has become a particularly stark access problem. In the UK, for example, medicines discovered and developed with substantial domestic scientific input have been licensed by the regulator yet have not been recommended for routine NHS use on cost-effectiveness grounds. Similar decisions arise wherever reimbursement is tied to an explicit willingness-to-pay threshold. For families, ‘approved but unavailable’ is an almost uniquely painful formulation – and one that no amount of health-economic modelling communicates well.^15,16

Our view: the sector has consistently under-invested in explaining what a clinically meaningful difference actually is. We have allowed ‘statistically significant’ and ‘life-changing’ to become synonyms in the hands of advocates, and antonyms in the hands of critics. Neither is accurate. A therapy that buys several months of retained independence is not a cure, and it is not nothing. Communicating that middle ground honestly – before the headlines are written, not after – is now a strategic imperative.

3. When the alternatives fail too

The most intellectually honest defence of amyloid has always been comparative: what else is there?

2025–2026 has tested that defence hard. Tau-directed approaches – long positioned as a potential driver of neurodegeneration, given the closer relationship between tau pathology and cognitive decline – have produced encouraging biomarker and early signal data while missing their primary clinical endpoints.¹⁷

This matters for how we interpret the criticism of amyloid. It is one thing to argue that the field backed the wrong target. It is another to recognise that every target is proving difficult in a disease that can begin decades before diagnosis, in an organ we cannot routinely biopsy, and in patients who have historically entered trials too late.

The more defensible conclusion is not ‘amyloid is wrong’ but ‘amyloid alone, given late, in unselected populations, is insufficient.’ That is a subtler claim – and a much harder one to headline.

4. The expanding target landscape

Beneath the noise, the pipeline has been reconstituting itself. Drug development in Alzheimer's now spans tau, neuroinflammation, metabolism and synaptic dysfunction, alongside a growing interest in precision medicine and combination approaches.– an approach that, as one biotech chief executive has noted, represents a deliberate departure from antibody-based strategies. The balance of the pipeline has shifted markedly from a field once dominated by anti-amyloid and anti-tau programmes toward alternative pathways.

Anti-amyloid antibodies remain, for now, the only approved disease-modifying option, but they are no longer the only serious idea.

The communications challenge is significant. The field is moving from a single story, which is easy to tell and easy to disprove, to a much broader one involving multiple targets and approaches. That story is harder to explain, but also more resilient. Experts in  scientific communications that can make this complexity understandable – showing why a more diverse pipeline reflects scientific progress – will be increasingly valuable to their clients.

5. Prevention and the risk of a false dichotomy

The most consequential development of 2026 may not have come from a pharmaceutical trial at all.

In July 2026, the WHO issued updated guidance concluding that up to 45% of dementia cases could be prevented or delayed by tackling risk factors over the course of a lifetime. These include tobacco and alcohol use, physical inactivity, social isolation, air pollution and non-communicable disease burden such as hypertension and diabetes.

This is an extraordinary figure, and it will inevitably be weaponised in the therapeutics debate: why spend on marginal antibodies when nearly half the burden is addressable through public health?

We would urge the sector to resist that framing, firmly and early. Prevention and treatment operate on different populations, different timescales and different budgets. Population-level risk reduction does nothing for the person diagnosed today; disease-modifying therapy does nothing for the 45%.¹⁹ A mature communications strategy positions them as complementary pillars of a single system.

Note, too, what the WHO figure implicitly concedes: even perfect execution leaves a majority of cases untouched. Prevention is not an argument against drug development. It is an argument for both – and that must be communicated clearly.

6. From clinic to kitchen table

One under-discussed development deserves more attention: the move towards giving some anti-amyloid treatments by subcutaneous injection (under the skin, rather than into a vein), including the possibility of starting treatment at home. Regulatory acceptance of home treatment changes the practicalities of treatment considerably – reducing dependence on infusion centres, easing the burden on caregivers and potentially widening geographic access.^20,21

It also changes the communication task. Home administration shifts responsibility for safety vigilance, particularly around amyloid-related imaging abnormalities, toward patients and families. Risk communication that was previously mediated by a clinical setting must now be designed to work at a kitchen table. That is a materially different brief, and one the industry has not yet fully reckoned with.

So, how do we respond?

At TVF, we’re putting these principles into practice:

• Separating the regulatory story from the scientific one. Much of the damage in this field came from conflating a contested approval decision with a contested scientific hypothesis. They are different questions and deserve different responses.
• Leading with how the treatment works, not how much we hope it will achieve. Audiences forgive modest effects. They do not forgive overstatement. Set the expectation before someone else sets it for you.
• Defining what meaningful benefit looks like. Agree, publish and repeat what constitutes a clinically important difference before the topline data arrive. Post hoc justification always reads as rationalisation.
• Treating negative trials as evidence, not embarrassment. A tau programme that misses its endpoint but shows movement in biomarkers has still taught the field something. Burying such results only feeds the narrative that the science is failing wholesale.
• Embracing the both/and. Prevention and treatment. Amyloid and tau. Immunity and clearance. Precision and population health. The field's credibility now depends on resisting false choices.
• Designing for the real world. As treatment moves into the home, communication needs to work for patients and families, not just clinicians.

Alzheimer's disease is not witnessing a failure of science. It is confronting a failure of narrative: a mismatch between the incremental, iterative, occasionally disappointing reality of translational neuroscience and the binary language of breakthrough and bust through which we have come to understand it.

The first anti-amyloid antibodies are unlikely to be remembered as transformative medicines. They may instead be remembered as the proof of concept that made transformative medicines possible – the first demonstration that the trajectory of this disease can be altered at all. Whether that becomes their lasting legacy will depend, in part, on how well the next five years are communicated.

That is work worth doing carefully.

By Dr Azhaar Ashraf

References

1. Edison, P. et a
2. Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial. Nat Med 32, 353–361 (2026).
3. Aducanumab Discontinued as an Alzheimer’s Treatment. https://www.alz.org/alzheimers-dementia/treatments/aducanumab (2021).
4. Cummings, J. L. et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer’s disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet 407, 2167–2179 (2026).
5. Cummings, J. et al. Alzheimer’s disease drug development pipeline: 2022. Alzheimer’s & Dementia: Translational Research & Clinical Interventions 8, e12295 (2022).
6. Lisa Kiani. The History of Alzheimer’s disease. https://www.nature.com/immersive/alzheimers-disease-history/index.html (2024).
7. Cummings, J. et al. Lecanemab: Appropriate Use Recommendations. J Prev Alzheimers Dis https://doi.org/10.14283/jpad.2023.30 (2023) doi:10.14283/jpad.2023.30.
8. van Dyck, C. H. et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med 388, 9–21 (2023).
9. Jessen, F. et al. Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses. J Prev Alzheimers Dis 13, 100605 (2026).
10. Sims, J. R. et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 330, 512–527 (2023).
11. Mintun, M. A. et al. Donanemab in Early Alzheimer’s Disease. N Engl J Med 384, 1691–1704 (2021).
12. van Dyck, C. H. et al. Long-term safety and efficacy of lecanemab in early Alzheimer’s disease: Results from the clarity AD open-label extension study. Alzheimers Dement 21, e70905 (2025).
13. Aljuhani, M., Ashraf, A. & Edison, P. Evaluating clinical meaningfulness of anti-β-amyloid therapies amidst amyloid-related imaging abnormalities concern in Alzheimer’s disease. Brain Commun 6, fcae435 (2024).
14. Nonino, F. et al. Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Cochrane Database Syst Rev 4, CD016297 (2026).
15. Snyder, H. M. et al. Recent Cochrane review has serious flaws: A perspective of clinicians and researchers from around the world. Alzheimers Dement 22, e71696 (2026).
16. New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE. https://www.nice.org.uk/news/articles/new-alzheimer-s-treatment-donanemab-does-not-currently-demonstrate-value-for-the-nhs-says-nice (2024).
17. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]. https://www.nice.org.uk/guidance/indevelopment/gid-ta11220.
18. Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease. https://investors.biogen.com/news-releases/news-release-details/biogen-presents-phase-2-celia-data-aaic-demonstrating-meaningful (2026).
19. Cummings, J. L. et al. Alzheimer’s disease drug development pipeline: 2026. Alzheimers Dement (N Y) 12, e70251 (2026).
20. New WHO guidelines: up to 45% of dementia risk could be prevented or delayed. https://www.who.int/news/item/15-07-2026-new-who-guidelines--up-to-45--of-dementia-risk-could-be-prevented-or-delayed (2026).
21. FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease. https://www.eisai.com/news/2026/news202640.html (2026).
22. Baraniuk, C. Alzheimer’s drug lecanemab: FDA approves easier initial use, with ‘huge implications’ for UK. BMJ 394, e100318 (2026).